The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Mazdutide is simultaneously an Eli Lilly compound, a Chinese pharmaceutical, and a Western research chemical — its origins, development trajectory, and current status reflect the increasingly globalized but jurisdictionally fragmented nature of modern drug development.
Mazdutide's pharmacological ancestry traces to Eli Lilly's exploration of the GLP-1R/GCGR dual agonist space — a mechanistic approach that Lilly was investigating in parallel with its GLP-1R/GIPR dual agonist program that eventually produced tirzepatide. LY3305677 was Lilly's GLP-1/glucagon dual agonist candidate. Rather than advancing it globally, Lilly licensed it to Innovent Biologics for development and commercialization specifically in China — a licensing model common in biopharma where companies monetize assets from one program while focusing internal resources on a prioritized compound (in Lilly's case, the tirzepatide program). Innovent Biologics, headquartered in Suzhou, is one of China's most sophisticated biopharmaceutical companies with multiple international-standard clinical development programs. Under the development code IBI362, Innovent built the entire clinical trial program for mazdutide in Chinese patient populations.
Oxyntomodulin context: mazdutide is described as a mammalian oxyntomodulin (OXM) analogue. OXM is an endogenous proglucagon-derived peptide secreted by intestinal L-cells post-meal — the same cells that secrete GLP-1. Like GLP-1, OXM activates the GLP-1 receptor; unlike GLP-1, OXM also activates the glucagon receptor, giving it dual receptor activity. Native OXM has a very short plasma half-life (~8-12 minutes) making it pharmacologically impractical. Mazdutide is an engineered analogue of OXM with structural modifications that extend its half-life to enable once-weekly dosing — the same lipidation and amino acid substitution engineering approach used across the GLP-1 class.
THE CENTRAL TENSION
Mazdutide is the world's first approved dual GCG/GLP-1 receptor agonist — a regulatory milestone that occurred in the world's most populous country in June 2025. It has Phase 3 data in tens of thousands of Chinese patients, NMPA approval for obesity and T2D, and publication in Nature. And virtually no one in the Western medical establishment is paying attention to it. The compound that is simultaneously approved and obscure reflects a broader reality: the pharmaceutical regulatory universe is jurisdictionally fragmented in ways that create information asymmetries. NMPA approval is a rigorous national regulatory evaluation — not equivalent to FDA approval, but not nothing. For community members in Western countries: mazdutide is a research chemical without FDA review, accessed without physician oversight, using quality-unverified research vendor products, for an indication where approved alternatives (semaglutide, tirzepatide) exist with FDA-reviewed safety and efficacy data. The NMPA approval changes the risk framing somewhat versus a purely preclinical compound — but does not substitute for the individual-level oversight that physician prescription provides.
Mazdutide and survodutide share the GLP-1R + GCGR dual mechanism but differ in origin, structure, development geography, and regulatory status. Understanding the comparison is essential for the community member choosing between them.
Feature
Mazdutide (IBI362)
Survodutide (BI 456906)
Developer
Innovent Biologics (China) / licensed from Eli Lilly
Boehringer Ingelheim (Germany) / Zealand Pharma (Denmark)
Molecular basis
Oxyntomodulin (OXM) analogue — endogenous GLP-1R + GCGR dual agonist
Synthetic peptide; not OXM-based but same receptor targets
Primary market
China (NMPA approved June + September 2025)
Global (Phase 3 ongoing; SYNCHRONIZE-1 positive April 2026)
Regulatory status
NMPA-approved for obesity (June 2025) and T2D (September 2025); no FDA/EMA filing
Not approved anywhere; SYNCHRONIZE-1 Phase 3 positive; NDA submission anticipated
Key Phase 3 obesity WL
Not yet fully published; GLORY-1 met all primary endpoints
SYNCHRONIZE-1: -16.6% at 76 weeks vs -3.2% placebo (April 2026)
MASH indication
Not primary focus; liver fat improvements documented in GLORY-1
Primary focus; FDA Breakthrough Therapy designation; LIVERAGE Phase 3 ongoing
T2D data
DREAMS-1 + DREAMS-2 published Nature December 2025; superior to dulaglutide
SYNCHRONIZE-2 (obesity + T2D) ongoing
Phase 3 journal
Nature (T2D)
NEJM (Phase 2 MASH); topline press release (Phase 3 obesity)
Community access
Gray market; research chemical; also available as pharmaceutical in China
Research chemical; no pharmaceutical availability outside trials
FDA path
No IND or NDA as of mid-2026; no Western development announced
Active development toward FDA submission post-Phase 3
The practical choice for community members: mazdutide has the regulatory approval (China) and the Nature publications; survodutide has the FDA Breakthrough Therapy designation for MASH and the most positive Phase 3 signal for Western regulatory submission. For MASH specifically, survodutide is the more strategically positioned compound in the Western pipeline. For a community member who wants access to a GLP-1/GCGR dual agonist with the most regulatory validation globally, mazdutide is the only currently approved version — but the research chemical access raises the same quality concerns as any unregulated injectable.
Oxyntomodulin is a 37-amino acid peptide produced by post-translational processing of proglucagon in intestinal L-cells. It contains the full glucagon sequence (1-29) extended by an 8-amino acid carboxy-terminal peptide — this structure gives it dual receptor activity: GLP-1R agonism (via the carboxy-terminal extension modifying the glucagon core) and GCGR agonism (via the glucagon 1-29 core sequence). In human physiology, OXM is released postprandially alongside GLP-1 and PYY as part of the intestinal satiety hormone response. OXM has lower affinity for both receptors than selective agonists — glucagon has higher GCGR affinity; GLP-1 has higher GLP-1R affinity — but its dual activity profile produces a combined metabolic effect that neither hormone alone achieves. Mazdutide preserves this dual receptor profile in an engineered, long-acting form.
Mazdutide's GLP-1R component drives the core GLP-1 pharmacology: appetite suppression through hypothalamic and brainstem GLP-1R activation; glucose-dependent insulin secretion from pancreatic beta cells; gastric emptying delay; and glucagon suppression (glucose-dependent). These effects are shared with all GLP-1 agonists — semaglutide, tirzepatide, liraglutide — and are responsible for the blood glucose lowering and weight loss via caloric restriction that are consistent across the class.
Mazdutide's glucagon receptor component produces the same set of direct hepatic effects as survodutide's GCGR agonism — hepatic fat oxidation, FGF21 induction, increased energy expenditure via thermogenesis — plus the same glycemic management challenge (glucagon drives glycogenolysis and gluconeogenesis) that the GLP-1 component neutralizes through glucose-dependent insulin secretion. The additional metabolic markers documented in mazdutide's clinical trials — reductions in liver fat content, liver enzymes (ALT/AST), blood uric acid, and triglycerides beyond what pure GLP-1 agonism produces — are consistent with the GCGR-mediated direct hepatic effects that distinguish the dual-agonist class from GLP-1 monotherapy.
Mazdutide has a robust Phase 3 program by any standard — multiple large trials, two NMPA approvals, and Nature publications. The important context: all trials were conducted in Chinese adults, and the evidence in non-Asian populations is limited.
Ji L, et al. (2021, EClinicalMedicine): Phase 1b randomized placebo-controlled trial; n=36 overweight and obese Chinese adults; IBI362 (mazdutide) at 3.0, 4.5, or 6.0mg weekly vs placebo; 12 weeks. Mean body weight reductions: 4.81% (3.0mg), 6.40% (4.5mg), 6.05% (6.0mg) vs 0.60% placebo. GI adverse events predominant (nausea, vomiting — consistent with GLP-1 class); no treatment-related serious adverse events. A parallel Phase 1b in Chinese adults with T2D (Jiang et al., 2022, Nature Communications) extended these observations to the diabetic population. These early dose-ranging studies established the pharmacokinetic and safety foundation for the Phase 3 program.
GLORY-1 is the pivotal Phase 3 obesity trial. Design: Chinese adults with overweight or obesity; once-weekly mazdutide vs placebo; 48-week primary assessment with longer follow-up. Results (reported 2024): all primary endpoints and key secondary endpoints met. At weeks 32 and 48, significant percentage body weight reduction from baseline vs placebo. Secondary outcomes: statistically significant improvements in waist circumference, blood lipid parameters, systolic blood pressure, serum uric acid, liver enzymes (ALT/AST), liver fat content, and insulin sensitivity vs placebo. These comprehensive metabolic improvements — particularly the liver fat and liver enzyme data — are consistent with the GCGR-mediated direct hepatic effects and distinguish mazdutide's metabolic profile from pure GLP-1 agonism. The specific percentage weight loss figures at 32 and 48 weeks from the full GLORY-1 publication are expected in peer-reviewed form in 2025-2026. The NMPA NDA acceptance (February 2024) and approval (June 2025) confirm the regulatory agency's evaluation of this data as sufficient for approval.
DREAMS-1 and DREAMS-2 (Dual GLP-1/Glucagon Receptor Agonist Mazdutide in Diabetes Studies) were the pivotal Phase 3 trials for the T2D indication. Both trials published as Accelerated Article Previews back-to-back in Nature, December 2025 — the most prestigious publication outlet for either trial in this chapter's entire evidence table. Design: Chinese adults with T2D; mazdutide vs dulaglutide (a standard GLP-1 agonist control). Primary endpoints: HbA1c reduction and body weight reduction. Results: mazdutide demonstrated superior efficacy vs dulaglutide for both glycemic control (HbA1c reduction) and weight reduction. Favorable safety profile consistent with GLP-1 class. These Nature publications represent the highest-evidence publication in the GCG/GLP-1 dual agonist class globally at time of writing — surpassing survodutide's NEJM Phase 2 in journal prestige, though Phase 3 vs Phase 2 context must be noted.
Trial
Indication
Design
Grade
Key Finding
Phase 1b Ji 2021 (EClinicalMedicine)
Obesity (Chinese)
DBRCT; n=36; 12 weeks
B
4.81-6.40% WL vs 0.60% placebo; safety established; dose-ranging
Phase 1b Jiang 2022 (Nature Comms)
T2D (Chinese)
DBRCT; dose-ranging; 12 weeks
B
Glycemic and weight reduction dose-response in T2D; safety profile
GLORY-1 Phase 3
Obesity (Chinese adults)
DBRCT; Phase 3; 48 weeks + extension
A
All primary and key secondary endpoints met; WL, waist, lipids, BP, uric acid, liver fat, ALT/AST all improved; basis for NMPA obesity approval June 2025
DREAMS-1 Phase 3 (Nature Dec 2025)
T2D (Chinese adults)
DBRCT; Phase 3; vs dulaglutide
A
Superior to dulaglutide for HbA1c reduction and weight reduction; basis for NMPA T2D approval Sept 2025
DREAMS-2 Phase 3 (Nature Dec 2025)
T2D (Chinese adults)
DBRCT; Phase 3; vs dulaglutide
A
Back-to-back confirmation of DREAMS-1 results in T2D population
Non-Chinese/Western population data
Any indication
None as of mid-2026
No grade
Not studied in Western populations; ethnicity and baseline BMI differences may affect translation
All of mazdutide's clinical evidence was generated in Chinese adults. This is not a disqualification but it is a pharmacological reality that requires explicit acknowledgment.
The GLP-1 class shows differential responses across ethnic groups — a well-documented finding across the semaglutide, tirzepatide, and liraglutide programs. The key differences between Asian/Chinese and Western obesity populations: Chinese adults typically have lower absolute BMI at equivalent metabolic risk — the Asian BMI obesity cutoff is lower (BMI ≥25 for overweight, ≥30 for obesity in Western guidelines vs lower thresholds often used in Asian clinical research). Baseline body weight in Chinese trial populations is substantially lower than in Western trials — this affects both the absolute weight loss in kg and the percentage weight loss at equivalent efficacy. Metabolic risk profiles differ — Chinese adults with obesity more frequently show central adiposity, metabolic liver disease, and T2D at lower BMI compared to Western populations with equivalent BMI. GLP-1 receptor expression and pharmacokinetics have some ethnic variation documented for other GLP-1 agents. The implication for evidence translation: mazdutide's Phase 3 weight loss percentages in Chinese adults are likely comparable to what the compound would produce in Western adults, but the absolute kg loss will be lower given lower baseline body weight. Whether the comprehensive metabolic benefits (liver fat, liver enzymes, uric acid, lipids) observed in the GLORY-1 Chinese population would be equivalent in predominantly European populations has not been tested.
THE NMPA APPROVAL — WHAT IT MEANS AND WHAT IT DOESN'T
China's National Medical Products Administration (NMPA) is a national regulatory authority that conducts rigorous, international-standard pharmaceutical reviews. NMPA approval means the compound has been evaluated by a sovereign regulatory body and found to have an acceptable benefit-risk profile for the approved indication in Chinese adults. NMPA approval does not mean: (1) FDA or EMA approval — those agencies conduct independent evaluations with potentially different standards, data requirements, and population considerations; (2) That the compound is safe and effective in non-Chinese populations — the NMPA reviewed Chinese trial data; (3) That quality of research chemical mazdutide available in Western markets meets the same standards as NMPA-approved pharmaceutical mazdutide manufactured by Innovent under cGMP. The NMPA approval meaningfully changes the evidence framing compared to a purely preclinical or Phase 2 compound — but it does not substitute for FDA review for Western community users.
Mazdutide's safety profile across Phase 1b and Phase 3 trials is consistent with the GLP-1 agonist class: nausea, vomiting, and diarrhea are the most common adverse events, concentrated during dose escalation, and managing with appropriate titration protocols. No unexpected safety signals were identified in the Phase 3 program that differed from established GLP-1 class safety. The NMPA's approval confirms the regulatory assessment that the benefit-risk profile is acceptable in the approved populations.
As a GLP-1 receptor agonist, mazdutide carries the same class-level medullary thyroid carcinoma (MTC) concern as all GLP-1 agonists — rodent C-cell hyperplasia driven by GLP-1R on thyroid C-cells. Additionally, the GCGR component introduces the same consideration noted for survodutide: glucagon receptors are also expressed on thyroid C-cells in some species, potentially adding a second C-cell signal. Contraindications expected to include personal or family history of MTC or MEN2, consistent with the GLP-1 class standard.
The GLP-1 component manages the glucagon-receptor-mediated hyperglycemia risk — glucose-dependent insulin secretion counterbalances GCGR-driven glycogenolysis. In the T2D trials, the combination produced net glycemic improvement (reduced HbA1c) rather than hyperglycemia, confirming that the GLP-1/GCGR balance manages the theoretical glycemic concern effectively in clinical practice.
NMPA approval means a regulatory authority evaluated the benefit-risk profile for a specific indication in Chinese adults under physician supervision with pharmaceutical-grade product. Community use of research chemical mazdutide without physician oversight, in non-Chinese populations, with unverified product quality, in potentially different dosing regimens, is a categorically different situation from the approved use. Approval provides evidence of the compound's pharmacological profile; it does not validate self-administration of research chemical versions.
Both are GLP-1R/GCGR dual agonists but they are structurally distinct compounds from different manufacturers with different pharmacological profiles, different Phase 3 populations, and different regulatory trajectories. Mazdutide is an OXM analogue; survodutide is a synthetic peptide with different structural engineering. Their GLP-1R/GCGR receptor selectivity ratios may differ, producing different balances between the two mechanisms at equivalent doses. No head-to-head comparison trial has been conducted.
This is an overcorrection. The fundamental pharmacology of GLP-1R and GCGR agonism is not ethnicity-specific — the mechanisms operate through the same receptors regardless of ancestry. The relevant differences between Chinese trial populations and Western users relate to baseline body weight (affecting absolute vs percentage outcomes), baseline BMI distribution, and possibly some pharmacokinetic parameters. The GI adverse event profile, mechanism of action, and broad safety signals from the NMPA program are informative for Western users — with the caveat that the specific dose-response may differ and efficacy in non-Chinese populations has not been confirmed by a dedicated trial.
Innovent Biologics press release, June 27, 2025. NMPA Approval of Mazdutide for Chronic Weight Management. [World's first GCG/GLP-1 dual agonist regulatory approval; NMPA approval for obesity in Chinese adults with overweight or obesity.]
Innovent Biologics press release, September 19, 2025. NMPA Approval of Mazdutide for T2D Glycemic Control. [Second NMPA approval; adults with type 2 diabetes; better than dulaglutide for both glucose lowering and weight reduction.]
DREAMS-1 and DREAMS-2 Phase 3 trials, Innovent Biologics / principal investigators at Chinese academic medical centres. Published as Accelerated Article Previews back-to-back in Nature, December 2025. [Phase 3 RCT vs dulaglutide in Chinese T2D adults; superior glycemic control and weight reduction; basis for NMPA T2D approval; highest-prestige publication in GCG/GLP-1 dual agonist class.]
Ji L, et al. (2021). Phase 1b study of IBI362 in Chinese adults with overweight or obesity. EClinicalMedicine. [First human data; dose-ranging; weight loss 4.81-6.40% at 12 weeks vs 0.60% placebo; no treatment-related serious AEs.]
Jiang G, et al. (2022). Phase 1b study of IBI362 in Chinese adults with T2D. Nature Communications. [Parallel Phase 1b in T2D population; dose-ranging; glycemic and weight results; safety profile.]
Son JW, et al. (2026). Expanding options for GLP-1-based medications in T2D and obesity. Endocrine Reviews. [Class review positioning mazdutide among dual and triple agonists; notes no FDA submission as of April 2026.]
Mazdutide is simultaneously the most regulated and the most overlooked GLP-1/GCGR dual agonist in the global marketplace — approved in the world's largest country, invisible in the West, and increasingly available as a research chemical everywhere.
The honest assessment: mazdutide has completed the regulatory journey that survodutide is still on. Two NMPA approvals (obesity June 2025, T2D September 2025), Phase 3 data published in Nature, a development program that Fierce Pharma called one of the top 10 most anticipated drugs of 2025. The compound is a genuine pharmaceutical with regulatory endorsement from a major national regulatory authority. Its absence from Western medical discourse reflects the Western regulatory ecosystem's structure rather than the compound's scientific merit. For community members: the NMPA approval provides meaningful reassurance about the compound's general safety and efficacy profile beyond what a research-chemical-only compound provides. The evidence in Chinese adults is not perfectly translatable to Western populations but is directionally informative. The remaining concerns are the same as for any research chemical: quality assurance of the specific product obtained; physician oversight for the metabolic condition being treated; and the absence of FDA review that would have provided additional safety assurance for Western populations specifically.
— End of Mazdutide —
THE PEPTIDE BIBLE | Mazdutide | For Research & Educational Purposes Only
Mazdutide (IBI362 / LY3305677): dual GLP-1R + GCGR agonist; mammalian oxyntomodulin (OXM) analogue. Developed by Innovent Biologics (China) under license from Eli Lilly (original Lilly designation LY3305677). Once-weekly SubQ injection. APPROVED: NMPA obesity June 27, 2025 (world's first approved GCG/GLP-1 dual agonist); NMPA T2D September 2025. NOT approved: FDA/EMA — no IND or NDA filed as of mid-2026. MECHANISM: GLP-1R component (appetite suppression; glucose-dependent insulin; glucagon suppression; gastric slowing) + GCGR component (direct hepatic fat oxidation; FGF21 induction; thermogenesis; lipolysis; suppressed hepatic lipogenesis) — GLP-1 neutralizes GCGR hyperglycemic risk. PHASE 1b: Ji 2021 (EClinicalMedicine): n=36 Chinese obese adults; 12 weeks; -4.81 to -6.40% WL vs -0.60% placebo; safety established. Jiang 2022 (Nature Comms): T2D Phase 1b parallel. PHASE 3 OBESITY (GLORY-1): Chinese adults with overweight/obesity; 48 weeks; all primary + key secondary endpoints met; WL + waist circumference, lipids, BP, uric acid, liver fat, ALT/AST all improved vs placebo; NDA accepted Feb 2024; NMPA approved June 2025. PHASE 3 T2D (DREAMS-1 + DREAMS-2): Nature Accelerated Article Previews December 2025; vs dulaglutide; mazdutide superior for both HbA1c reduction and weight reduction; basis for NMPA T2D approval Sept 2025. POPULATION NOTE: all trials in Chinese adults; baseline BMI and weight lower than Western trials; efficacy directionally translatable but not confirmed in Western populations specifically. NMPA APPROVAL: rigorous national regulatory review; different from FDA/EMA; approves for Chinese adults under physician supervision with pharmaceutical-grade product. vs SURVODUTIDE: both GLP-1R+GCGR; mazdutide = OXM analogue, NMPA-approved; survodutide = synthetic, FDA Breakthrough Therapy MASH, SYNCHRONIZE-1 positive. MASH: mazdutide shows liver fat/enzyme improvements but no dedicated MASH program; survodutide is the MASH-optimized option. SAFETY: GI AEs (nausea, vomiting, diarrhea) — class consistent; MTC class concern (GLP-1R + potential GCGR on C-cells); glycemia managed by GLP-1 component. COMMUNITY: gray-market research chemical in West; pharmaceutical in China. WADA: not listed.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.